Psilocybin therapy research for addiction has shown encouraging results in supervised studies for alcohol use disorder and smoking cessation, with outcomes that often improve after one or two dosing sessions paired with structured therapy support, while researchers still need larger trials, longer follow-up, and clearer comparisons across protocols.
What researchers mean by psilocybin therapy for addiction
In addiction research, psilocybin therapy usually means a supervised program that includes preparation sessions, one or more dosing sessions in a controlled setting, and follow-up sessions that focus on behavior change and relapse prevention. Many studies also pair psilocybin with a specific counseling approach and set a quit date or reduction goal, then measure outcomes over months.
This definition is important when you read results. In most published studies, the medication session is not treated as a stand-alone event. The protocol is the intervention.
Why alcohol and smoking research gets most of the attention
Alcohol use disorder and tobacco use disorder have two things that help research move faster.
First, outcomes can be measured in concrete ways. Alcohol studies often track heavy drinking days and drinks per day. Smoking studies can use biological verification alongside self-report. (PubMed)
Second, these studies can set clear targets such as abstinence or reduction, then follow participants over months to see how stable changes are.
What alcohol use disorder studies have shown
The strongest modern alcohol evidence includes a randomized clinical trial that compared psilocybin plus psychotherapy with an active placebo plus psychotherapy over a long follow-up window. In that trial, the percentage of heavy drinking days during the double-blind period was lower in the psilocybin group than in the comparison group, and average daily drinking was also lower. (PubMed)
One practical detail you will see in alcohol trials is how they define and track heavy drinking. The primary outcome is often the percentage of days that meet a heavy drinking threshold across a defined period, such as multiple months. This helps researchers compare participants with different baseline drinking patterns and track change over time instead of relying on a single check-in. (PubMed)
You will also see alcohol trials report related outcomes such as
- percentage of drinking days overall
- number of standard drinks per day
- craving measures
- adverse events during and after dosing
These secondary outcomes help interpret what the primary outcome really means for daily life and risk. (PubMed)
Why alcohol trial results can vary across papers
Even within alcohol use disorder research, protocols differ in ways that can change outcomes.
Dose and session count varies. Some protocols use one high-dose session. Others use two dosing sessions. Follow-up schedules and counseling hours also vary. (PMC)
Participant populations vary too. Some trials enroll people with severe alcohol use disorder. Others enroll a broader range. Screening rules also shape who participates. (ClinicalTrials.gov)
Because of this, one trial can show a strong reduction in heavy drinking days while another can show smaller effects, even when both are well run. A recent relapse prevention study reported that a single dose paired with a defined amount of psychotherapy did not produce a statistically significant reduction in alcohol use in that design. That kind of result helps clarify how much session count and therapy dose might affect outcomes. (The Lancet)
What smoking cessation studies have shown
The modern smoking evidence began with a structured pilot program that paired cognitive and behavioral support with multiple psilocybin sessions scheduled around a target quit date. The early pilot work described a 15-week program with moderate and high doses and sessions timed to support quit attempts and maintenance. (PMC)
Long-term follow-up reporting from this program found biologically verified abstinence rates that remained high relative to typical cessation outcomes. At 12 months, two-thirds of participants were confirmed abstinent, and at longer follow-up, 60 percent were confirmed abstinent among those assessed. (PubMed)
For smoking research, the use of biological verification is a key design feature. It reduces bias from self-report and gives a clearer view of abstinence over time. (PMC)
What to take from smoking results as a beginner
These smoking studies are small and they are not the final word on effectiveness across diverse populations. They do show that a structured program pairing therapy with psilocybin can produce durable abstinence in a closely monitored setting, and they show that long follow-up is feasible in this line of research. (PMC)
They also highlight a broader point that applies across addiction research. Studies are often testing a full change model that includes motivation, skills practice, and follow-up support, with psilocybin used inside that model.
Outcomes researchers track in addiction studies
If you want to read addiction trials with less confusion, start with what is being measured and when it is measured.
For alcohol use disorder, common outcomes include
- percentage of heavy drinking days over a defined period
- drinks per day or per drinking day
- percent days abstinent
- craving scores and related self-report measures
For tobacco use disorder, common outcomes include
- biologically verified abstinence at set timepoints such as 6 months and 12 months
- point prevalence abstinence such as 7-day or 30-day windows
- continuous abstinence measures over longer spans
These outcome choices affect how strong a result looks. A trial can show a clear difference in heavy drinking days while showing smaller differences in complete abstinence. A smoking study can show strong point prevalence abstinence while continuous abstinence looks lower. That is why it helps to read the exact outcome definitions. (PubMed)
What safety screening usually includes
Safety screening is central in addiction studies because participants can have medical risks, psychiatric risks, or both.
Many protocols screen for cardiovascular risk, uncontrolled hypertension, and other conditions that could raise risk during acute effects, since heart rate and blood pressure can rise during a dosing session. (PMC)
Protocols also screen for psychiatric histories that may raise the risk of destabilization. These exclusions often address prior psychotic disorders, bipolar disorder, and certain other conditions depending on the study. This step affects how broadly results apply. It also shapes the safety profile reported in published trials because the study population is selected. (Frontiers)
Alcohol studies may add extra safety rules related to withdrawal risk and recent heavy use. Tobacco studies may screen for medical conditions where nicotine withdrawal, stress responses, or medication interactions could be relevant. The exact criteria vary by study. (ClinicalTrials.gov)
What a typical supervised protocol looks like
Addiction protocols usually include several parts that repeat across studies.
Preparation
You meet with the therapy team before dosing. Sessions often cover expectations, coping skills for difficult emotions, relapse prevention planning, and practical support planning for the days after dosing. In smoking studies, preparation often includes quit planning and skills practice. In alcohol studies, preparation often includes goal setting and relapse risk planning. (PMC)
Dosing sessions
Dosing is supervised in a controlled setting. Staff monitor you, support you through periods of distress, and follow a plan for safety if anxiety or agitation rises. Trials describe this setting because it is part of the intervention and part of the safety plan. (PMC)
Follow-up and behavior support
Follow-up visits focus on processing what came up, then applying it to habits, triggers, and daily routines. In addiction research, this often includes skills practice, accountability, and relapse prevention planning rather than relying on insight alone. (Frontiers)
Why results can be hard to compare across studies
Even if you stay focused on alcohol and tobacco, comparing studies can be difficult for several reasons.
Blinding is hard in psychedelic trials because participants may infer assignment based on subjective effects. That can influence self-report outcomes, especially when motivation and expectancy are part of addiction recovery. (Frontiers)
Therapy time differs. Some studies include many hours of counseling. Others include less. Since the intervention is a package, differences in counseling hours can change outcomes. (Frontiers)
Outcome windows differ. One alcohol trial may report outcomes across 32 weeks. Another may focus on 12 weeks. Smoking studies may emphasize 12-month outcomes and longer follow-up. These windows change how you interpret durability. (PubMed)
Participant differences also shape results. Severity, comorbid depression or anxiety, medication status, and prior treatment history can vary. Even when two studies share a diagnosis label, they can enroll very different populations. (ClinicalTrials.gov)
What systematic reviews say about addiction evidence overall
Systematic reviews that look across addiction indications often describe the evidence as promising while still limited by small samples and risk of bias concerns. A 2023 review focused on psilocybin for alcohol and tobacco identified only a small number of modern trials and noted that bias risk ranged from some concerns to critical depending on design. (Frontiers)
More recent reviews and meta-analyses include a growing list of ongoing clinical trials registered in trial databases, which shows that the pipeline is expanding. These papers often emphasize that more randomized data is needed and that safety reporting standards and protocol consistency will be important as studies scale. (ScienceDirect)
If you want a simple read of what this means today, it means the alcohol trial data is stronger than the smoking data in terms of randomized controlled evidence, and the smoking data is notable for long-term abstinence reporting in a small sample. Across both, larger trials will decide how reliable effects are across diverse participants and real-world settings. (PubMed)
What to watch for as new addiction studies are published
When you read a new paper or a trial update, focus on a few design elements.
- randomization and the control condition
- dosing schedule and number of sessions
- counseling hours and follow-up schedule
- the primary outcome and how it is defined
- how missing data is handled
- adverse event reporting detail and follow-up length
Trial registry entries can help you interpret published results because they list planned endpoints and timelines. If you are already reading about how trials are designed and compared, it can help to scan a single hub of profiles like the clinicals page to keep designs straight across studies.
If you want broader context on how research programs think about study design and measurement, the way research questions are framed in research can also help while you are reading protocols and endpoints.
Near the end, here is where we fit. We are Rose Hill Life Sciences, a psychedelic research organization specializing in the production and research of Psilocybe cubensis, operating at the intersection of science and therapeutic integration, and we are based in Massachusetts.
